Skip to main content
. Author manuscript; available in PMC: 2013 Dec 12.
Published in final edited form as: J Genet Genomics. 2013 Feb 10;40(3):10.1016/j.jgg.2013.02.001. doi: 10.1016/j.jgg.2013.02.001

Fig. 3. The role of RBX2/SAG in skin cancer.

Fig. 3

Transgenic SAG expression inhibits DMBA/TPA-induced carcinogenesis by inactivating AP1 via targeting the c-Jun oncoprotein for degradation at the early stage, but promotes skin carcinogenesis by activating NF-κB via targeting the IκB tumor suppressor for degradation at the later stage. In addition, SAG regulates UVB-mediated skin hyperplasia via promoting the degradation of both p27 and c-Jun.